In our clinical observations, immunohistochemistry results revealed a positive correlation between tumor‐p‐Src or p‐Akt and pericyte‐IL32 levels in our EGFR‐mutated patient cohort (Figures 4I,J). This evidence concerns the gene IL32 and neoplasm.